enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Update

enGene Holdings Inc. (NASDAQ:ENGNW) was the target of a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 7,800 shares, a growth of 7,700.0% from the August 31st total of 100 shares. Based on an average trading volume of 5,500 shares, the short-interest ratio is currently 1.4 days.

enGene Stock Performance

Shares of enGene stock opened at $2.10 on Friday. enGene has a 1 year low of $0.39 and a 1 year high of $6.50. The company has a 50 day simple moving average of $1.18 and a two-hundred day simple moving average of $2.55.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.